Novo Nordisk’s Wegovy weight loss pills are growing in popularity.
Parenting | Getty Images
Novo Nordisk It will offer weight loss pills for less than half of the monthly price, Wednesday said. New Direct Consumer Online Pharmacy.
Cash payment Millions of patients without insurance can offer issuances, such as those using Medicare. Its purpose is to make Wegovy available to more people, while also ensuring patients use branded medications rather than cheaper compound imitators, which exploded when they recently addressed the drug shortage at Novo Nordisk.
The pharmacy, called NovoCare, will allow patients to pay $499 a month in cash to pay for weekly medications. Wegovy’s price before insurance and other rebates is almost $1,350 per month.
The site can also deliver Wegovy prescriptions directly to the patient’s home through professional pharmacy partners. Novocare will also provide supplemental reminders and provide real-time support from company case managers, as well as other patient support services.
“There are another option for patients and prescribers to easily access all doses of FDA-approved Wegovy, while our high-quality pens cost less,” Dave Moore, executive vice president of operations and global business development at the U.S., said in a statement.
The Danish producer’s move follows a similar strategy from its main rival, Eli Lilly. The two companies are working to dominate the market for so-called GLP-1, which mimics certain gut hormones to suppress appetite and regulate blood sugar.
Eli Lilly in January 2024 emission Its own direct-to-consumer online pharmacy LillyDirect to help patients get weight loss pills Zepbough.
The website allows eligible patients to obtain prescriptions through telemedicine providers and can provide delivery services. Recently, LillyDirect also began to provide Zepboughn Single dose vial is half of its usual $1,000 per month or less.
In recent months, the Food and Drug Administration has announced shortages in the United States in Zepbough and Wegovy. This decision will prevent some composite pharmacies from creating unapproved injection versions.
This story is developing. Please check it for updates.
